<table border="0" id="id_ecb9340e-a4db-4d1b-8727-1553504b866e" width="0.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<tbody>
<tr id="id_e50292f5-944b-4e4e-ad6b-8aba2e50315e" stylecode="Toprule">
<td align="center" stylecode="Lrule Rrule" valign="top">Pediatric Study Population<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Number of Subjects<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">T<sub>max</sub>
<br/>(h)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">t<sub>½</sub>
<br/>(h)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">Cl/F<br/>(mL/min/kg)<br/>
</td>
</tr>
<tr id="id_982d0790-14b9-4297-91fe-26fe06bde45a">
<td align="left" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Ages 10 months–5.3 years </content> <br/>   Patients taking carbamazepine, phenytoin, phenobarbital, or primidone<sup>a</sup>
<br/>   Patients taking AEDs with no known effect on the apparent clearance of lamotrigine<br/>   Patients taking valproate only <br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>10<br/>  <br/>  <br/>7<br/>  <br/>  <br/>8<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>3.0<br/>(1.0-5.9)<br/>  <br/>5.2<br/>(2.9-6.1)<br/>  <br/>2.9<br/>(1.0-6.0)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>7.7<br/>(5.7-11.4)<br/>  <br/>19.0<br/>(12.9-27.1)<br/> <br/>44.9<br/>(29.5-52.5)<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">  <br/>3.62<br/>(2.44-5.28)<br/>  <br/>1.2<br/>(0.75-2.42)<br/>  <br/>0.47<br/>(0.23-0.77)<br/>
</td>
</tr>
<tr id="id_cfca93b9-e056-4d21-84c2-899f11257b53">
<td align="left" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Ages 5-11 years</content> <br/>   Patients taking carbamazepine,   phenytoin, phenobarbital, or primidone<sup>a</sup>
<br/>   Patients taking carbamazepine, phenytoin, phenobarbital, or primidone<sup>a</sup> plus valproate<br/>   Patients taking valproate only<sup>b</sup>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>7<br/>  <br/>  <br/>8<br/>  <br/>  <br/>3<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>1.6<br/>(1.0-3.0)<br/>  <br/>3.3<br/>(1.0-6.4)<br/>  <br/>4.5<br/>(3.0-6.0)<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>7.0<br/>(3.8-9.8)<br/>  <br/>19.1<br/>(7.0-31.2)<br/>  <br/>65.8<br/>(50.7-73.7)<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">  <br/>2.54<br/>(1.35-5.58)<br/>  <br/>0.89<br/>(0.39-1.93)<br/>  <br/>0.24<br/>(0.21-0.26)<br/>
</td>
</tr>
<tr id="id_74b67f3c-ee11-4769-98a2-29a20f930867" stylecode="Botrule">
<td align="left" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Ages 13-18 years</content> <br/>   Patients taking carbamazepine, phenytoin, phenobarbital, or primidone<sup>a</sup>
<br/>   Patients taking carbamazepine, phenytoin, phenobarbital, or primidone<sup>a</sup> plus valproate<br/>   Patients taking valproate only<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>11<br/>  <br/>  <br/>8<br/>  <br/>  <br/>4<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>
<sup>c</sup>
<br/>  <br/>  <br/>
<sup>c</sup>
<br/>  <br/>  <br/>
<sup>c</sup>
<br/>
</td>
<td align="center" stylecode="Rrule" valign="top">  <br/>
<sup>c</sup>
<br/>  <br/>  <br/>
<sup>c</sup>
<br/>  <br/>  <br/>
<sup>c</sup>
<br/>
</td>
<td align="left" stylecode="Rrule" valign="top">  <br/>1.3<br/>  <br/>  <br/>0.5<br/>  <br/>  <br/>0.3<br/>
</td>
</tr>
</tbody>
</table>